NCT03701295View on ClinicalTrials.gov

Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 6, 2020

Primary Completion Date

December 8, 2020

Study Completion Date

January 12, 2021

Conditions
Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLLLeukemia CutisRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine

Given IV or SC

DRUG

Pinometostat

Given IV

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03701295 - Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement | Biotech Hunter | Biotech Hunter